Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs

Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, JapanCorrespondence[email protected]

Tsukasa MatsubaraDepartment of Orthopedics, Matsubara Mayflower Hospital, Hyogo, Japan

Yukitomo UrataDepartment of Rheumatology, Seihoku Chuo Hospital, United Municipalities of Tshugaru, Aomori, Japan

Eiichi SuematsuDepartment of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

Shuji OhtaDepartment of Rheumatology, Taga General Hospital, Ibaraki, Japan

Shigeru HonjoHonjo Rheumatism Clinic, Toyama, Japan

Tohru AbeDivision of Rheumatology, Clinical Immunology, Saitama Medical Center, Saitama Medical School, Saitama, Japan

Ami YamamotoBristol-Myers KK, Tokyo, Japan

Nobuyuki MiyasakaDepartment of Medicine and Rheumatology, and Global Center of Excellence, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

& The Japan Abatacept Study Group show all

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date